Unsuspected PE Does Not Up Mortality Risk in Cancer Patients

Share this article:
Unsuspected PE Does Not Up Mortality Risk in Cancer Patients
Unsuspected PE Does Not Up Mortality Risk in Cancer Patients

(HealthDay News) -- Cancer patients with an unsuspected pulmonary embolism (UPE) do not have an increased mortality risk and have a similar risk of recurrent venous thromboembolism (VTE) to those with clinically suspected pulmonary embolism (PE), according to research published online July 27 in the Journal of Thrombosis and Haemostasis.

To examine the risk factors and outcome of UPE in patients with cancer, M. Sahut D'Izarn, M.D., of the Hôpital Européen Georges Pompidou in Paris, and colleagues conducted a retrospective chart-review study involving 66 cancer patients with UPE who were compared with two control groups: 132 cancer patients without PE and 65 cancer patients with clinically suspected PE.

The researchers found that 40.9 percent of patients with UPE had symptoms suggestive of PE. Factors that were significantly associated with UPE included performance status >2 (odds ratio [OR], 7.31), recent chemotherapy (OR, 4.62), previous VTE (OR, 4.47), adenocarcinoma (OR, 4.45), and advanced age (OR, 1.18). After adjustment for performance status and tumor stage there was no significant difference in the six-month mortality for patients with UPE and those without PE. Compared with patients with clinically suspected PE, those with UPE were more likely to have a central venous catheter and chemotherapy and less likely to have a proximal clot. The rate of recurrent VTE was similar between groups.

"The results of this study suggest that UPE is associated with poor performance status, adenocarcinoma, previous VTE, and recent chemotherapy," the authors write. "After adjusting for performance status and cancer stage, UPE was not associated with a decrease in the survival rate."

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Poor parent-provider communication seen in advanced pediatric cancer

Poor parent-provider communication seen in advanced pediatric cancer

For pediatric patients with advanced cancer, parent-provider concordance is poor regarding prognosis and goals of care, according to a study.

Testicular cancer on the rise for young U.S. Hispanics

Testicular cancer on the rise for young U.S. ...

An increase in incidence of testicular germ cell tumors in Hispanic adolescents and young adults in the United States has been observed.

Rates of observation as prostate cancer management vary

Rates of observation as prostate cancer management vary

Rates of observation as management for low-risk prostate cancer vary widely, and primary ADT is not tied to better survival for men with localized prostate cancer.